A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Psychomotor Effect of VI-0521 in Healthy Overweight and Obese Subjects.

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Psychomotor Effect of VI-0521 in Healthy Overweight and Obese Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2013

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Sponsors VIVUS
  • Most Recent Events

    • 14 Nov 2009 Actual initiation date (Dec 2008), actual end date (May 2009) and actual number of patients (80) added as reported by ClinicalTrials.gov.
    • 14 Nov 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top